Humana · Anti Amyloid Kisunla · US health-plan appeal rights

Anti Amyloid Kisunla denied due to quantity / dose limits by Humana?

Q: How long do I have to appeal a Humana Anti Amyloid Kisunla denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Quantity-limit denials usually flip when the appeal documents the clinically appropriate dose for the patient's weight, kidney function, or escalation schedule, citing the FDA label or specialty-society guideline.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Medicare Advantage — follows CMS NCD 200.3 (anti-amyloid CED)

The Humana angle on Anti Amyloid Kisunla

## Why Humana Applied Quantity Limits to Kisunla — and How to Appeal

A quantity-limit denial for Kisunla (donanemab) means Humana's system flagged that the requested amount exceeds the quantity the plan pre-authorizes per dispensing period. For an infused biologic like Kisunla, this often reflects a mismatch between how the infusion is billed and the plan's expected units, or a limit that does not align with the dosing schedule in the FDA-approved prescribing information.

## Why This Denial Happens

Quantity limits on infused anti-amyloid therapies are often set based on a default unit count that does not account for weight-based or schedule-based variations in the prescribing label. If the infusion center bills in a different unit denomination than the plan expects, the system may flag the claim as exceeding the limit even when the actual dose is consistent with the label. A quantity-limit denial is not a finding that the drug is medically unnecessary — it is a formulary-management trigger.

## Federal Appeal Rights

Internal appeal (ACA §2719 / ERISA §503): Submit a written appeal within the timeframe on the denial notice. Request a full-and-fair review by a reviewer not involved in the initial determination.
Expedited appeal: Available if your physician certifies that the standard timeline poses a risk to your health. Humana must respond within 72 hours of an expedited request.
External review: If the internal appeal fails, you are entitled to independent external review. The four-month window to request external review typically begins at the final internal denial. The IRO decision is binding.

## Documentation to Gather

1. FDA-approved prescribing label — Print the current label from the FDA website and highlight the dosing and administration section. This is your benchmark for what constitutes a medically appropriate quantity. 2. Infusion order and billing codes — Obtain the infusion order from the prescribing neurologist and the HCPCS/NDC codes used by the infusion center. Compare these to what Humana's quantity limit specifies. 3. Prescriber medical-necessity letter — Ask the neurologist to certify that the prescribed quantity and schedule conform to the FDA-approved dosing regimen and that a reduction in quantity would compromise clinical outcomes. 4. Humana's quantity-limit policy — Request the specific coverage policy page that defines the limit. If the limit is lower than what the FDA label specifies, that discrepancy is the core of your appeal.

## Criteria-Mapping Structure for Your Appeal

Map Humana's quantity limit against the FDA label and your specific infusion order:

| Factor | Humana Limit | FDA Label | Your Order | |---|---|---|---| | Units per infusion | Per Humana policy | Per prescribing information | Per infusion order | | Frequency per treatment period | Per Humana policy | Per prescribing information | Per neurologist order | | Total treatment course | Per Humana policy | Per prescribing information | Per treatment plan |

If any Humana limit falls below what the FDA label specifies, state explicitly in your appeal that requiring a quantity below the labeled dose constitutes denial of medically necessary treatment and ask Humana to cite the clinical basis for the restriction.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Anti Amyloid Kisunla

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.